Skip to content

Study · Animal study (in vivo) · mouse · 2005

3 results

Antitumor activation of peritoneal macrophages by thymosin alpha-1.

Shrivastava P, Singh SM, Singh N

Cancer investigation1 Jan 2005Cited by 12 (Europe PMC)

PMID16100944 (opens in a new tab)DOI10.1081/cnv-58813 (opens in a new tab)PepBankPUB-16100944
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with Dalton's lymphoma, adoptive transfer of peritoneal macrophages treated with thymosin alpha‑1 prolonged survival time.

    In plain wordsIn mice with a T-cell lymphoma, transfer of macrophages treated with thymosin alpha‑1 lengthened survival.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSurvival time of tumor-bearing mice
    Study

    mousen: not reported in source

    Dalton's lymphoma
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · adoptive transfer of thyalpha1-treated peritoneal macrophagesAs given in this study (mouse).

    Source sentences

    Summary
    adoptive transfer of peritoneal macrophages treated with thyalpha1 to mice bearing spontaneous T-cell lymphoma designated as Dalton's lymphoma (DL) resulted in the prolongation of the survival time of tumor-bearing mice.
  2. 02LabEx vivo tissueActivity measurement

    Different tissue macrophages showed a differential response to thymosin alpha‑1 in activation tests.

    In plain wordsIn lab tests, different kinds of tissue macrophages responded differently to thymosin alpha‑1.

    Peptide
    Thymosin alpha-1
    Outcome
    MixedActivation response of tissue macrophages
    Study

    n: not reported in source

    Tissue macrophages treated with thyalpha1
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · in vitroAs given in this study.

    Source sentences

    Summary
    Tissue macrophages showed differential response to thyalpha1
  3. 03LabEx vivo tissueMechanism

    Thymosin alpha‑1 enhanced the antitumor activity of macrophages through their production of macrophage-activating cytokines that act in an autocrine manner.

    In plain wordsIn lab tests, thymosin alpha‑1 made macrophages more active against tumors by raising their own signalling proteins.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseMacrophage antitumor activity and cytokine production
    Study

    n: not reported in source

    Macrophages treated with thyalpha1
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · in vitroAs given in this study.

    Source sentences

    Summary
    The mechanism of macrophage therapy-dependent tumor regression was enhanced antitumor activity of macrophages in response to thyalpha1 treatment via their production of macrophage-activating cytokines that act in autocrine manner.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.